<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787304</url>
  </required_header>
  <id_info>
    <org_study_id>SHP626-201</org_study_id>
    <secondary_id>2016-000203-82</secondary_id>
    <nct_id>NCT02787304</nct_id>
  </id_info>
  <brief_title>Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment volixibat (SHP626)
      is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 24, 2016</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Binary response indicating (yes/no) whether a subject responded at week 48 with a reduction of at least 2 points, without worsening of fibrosis, from baseline nonalcoholic fatty liver disease (NAFLD) activity score (NAS). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Liver Histology</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change in liver histology will be measured by the individual NAS components (ballooning, inflammation, steatosis). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis (assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Hepatic Steatosis</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change in hepatic steatosis will be evaluated by measuring the reduction of liver fat with magnetic resonance imaging-proton density fat-fraction (MRI-PDFF) and stratified by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Liver Histology</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change in liver histology will be measured by fibrosis stage. Fibrosis stage is assessed on a scale of 0-4 with higher scores indicating more severe disease and lower scores indicating less severe disease (F0 = no fibrosis, F4 = cirrhosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Resolution of NASH at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Resolution of NASH is defined as total absence of ballooning [score = 0], absent or mild inflammation [score 0-1], steatosis can be present [score 0-3]) without worsening of fibrosis as assessed by liver histology at Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Serum Liver-related Biochemistry</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Serum liver-related biochemistry will be analysed by measuring alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Serum Liver-related Biochemistry</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Serum liver-related biochemistry will be analysed by measuring total bilirubin (TB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Metabolic Indicators</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Metabolic indicators will be assessed by measuring fasting serum glucose levels and insulin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Metabolic Indicators</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Metabolic indicators will be assessed by measuring hemoglobin A1c (HbA1c).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Serum Lipids</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Serum lipids level will be measured by calculating fasting total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglycerides.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>SHP626 5 Milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP626 10 Milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP626 20 Milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP626</intervention_name>
    <description>5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
    <arm_group_label>SHP626 10 Milligram (mg)</arm_group_label>
    <arm_group_label>SHP626 20 Milligram (mg)</arm_group_label>
    <arm_group_label>SHP626 5 Milligram (mg)</arm_group_label>
    <other_name>Volixibat (SHP626)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          2. Ability to voluntarily provide written, signed, and dated (personally or via a legally
             authorized representative, as applicable) informed consent to participate in the
             study.

          3. Age 18-80 years inclusive. This inclusion criterion will only be assessed at the first
             screening visit.

          4. Male, or non-pregnant, non-lactating female, who is sexually active and who agrees to
             comply with the contraceptive requirements of the protocol, or females of
             non-childbearing potential. Males and females of child-bearing potential who are
             sexually active must agree to use acceptable contraception during the study and for 30
             days following the last dose of the investigational product (IP).

          5. Presence of greater than equals to (&gt;=) 5 percent (%) steatosis on screening magnetic
             resonance imaging (MRI) from a centrally read radiologist performed either during the
             screening period or within 6 months prior to the first visit.

          6. Histologic confirmation of nonalcoholic steatohepatitis (NASH) without cirrhosis
             (F0-F3) from a centrally read liver biopsy performed either during the screening
             period or within 6 months prior to the first visit with a NAS of &gt;=4 with a score of
             at least 1 in each component (steatosis, lobular inflammation, and hepatocyte
             ballooning).

        Exclusion Criteria:

          1. Presence of or history of cirrhosis or evidence of decompensated liver disease
             (example: ascites, variceal bleeding, etc.) or hepatocellular carcinoma.

          2. History or presence of other concomitant liver disease as assessed by the investigator
             or determined by laboratory findings including, but not limited to: active hepatitis B
             virus (HBV) infection (hepatitis B surface antigen [HBsAg] positive and/or hepatitis B
             virus deoxyribonucleic acid (HBVDNA) positive; subjects who are hepatitis B core
             antibody [HBcAb] positive may be eligible as long as HBsAg is negative and HBVDNA is
             non detectable), active hepatitis C virus (HCV) infection (prior exposure to HCV
             [defined as HCVAb positive] without a current or prior history of a detectable HCVRNA)
             may be eligible, alcoholic liver disease, proven autoimmune hepatitis, primary biliary
             cirrhosis (PBC), primary sclerosing cholangitis (PSC), hemochromatosis, Wilson's
             disease, alpha-1 antitrypsin deficiency, bile duct obstruction, liver primary or
             metastatic cancer.

          3. Current or recurrent disease that could affect the action, absorption, disposition, or
             laboratory assessment of the IP (including bile salt metabolism in the intestine)
             example (e.g,) uncontrolled inflammatory bowel disease, uncontrolled celiac disease,
             gastric bypass procedures (gastric lap band or gastric sleeve is acceptable), ileal or
             ileocecal resection, uncontrolled irritable bowel syndrome with predominant diarrhea,
             or history of chronic diarrhea or loose stools of any etiology.

          4. Weight change &gt;=5% after qualifying liver biopsy and/or MRI performed. If the subject
             had a liver biopsy and/or MRI within 6 months of screening, but experienced a weight
             change of &gt;=5% since the date of liver biopsy and/or MRI, the liver biopsy and/or MRI
             must be repeated at screening.

          5. Contraindications to MRI (e.g, claustrophobia, coronary stents, coronary implantable
             devices, girth, etc.). Stents or other devices may be allowed, at the investigator's
             discretion, if they do not interfere with the functioning of the MRI machine.

          6. Current or relevant history of physical or psychiatric illness, any medical disorder
             that may require treatment or make the subject unlikely to complete the study.

          7. Treatment with Vitamin E, thiazolidinediones (TZD), or glucagon-like peptide-1
             receptor agonists (GLP-1 RA) unless subject on a stable dose for 6 months prior to
             qualifying liver biopsy and not initiated after qualifying liver biopsy and will
             continue the same dosing regimen throughout study participation.

          8. Uncontrolled diabetes defined as HbA1c of &gt;=9.5% within 60 days prior to enrollment.

          9. Current use of any medication (including over-the-counter, herbal, or homeopathic
             preparations) that could affect the action, absorption, or disposition of the IP, or
             clinical or laboratory assessment. (Current use is defined as use within 14 days of
             screening). Subjects currently taking insulin will not be excluded; however, they must
             be on a stable dose for at least 30 days prior to screening, or a sliding scale of
             insulin is allowed as long as the subject's HbA1c remains less than (&lt;) 9.5%.

         10. Use of drugs, herbs or supplements historically associated with causing or worsening
             NAFLD/NASH for less than 6 months prior to liver biopsy, or initiated any time after
             liver biopsy performed, including the use of total parenteral nutrition (TPN).

         11. Serum aspartate aminotransferase (AST) greater than (&gt;) 7 times upper limit of normal
             (ULN) at screening.

         12. Serum alanine aminotransferase (ALT) &gt;7 times ULN at screening.

         13. Elevated serum creatinine &gt;=2.0 milligram/deciliter (mg/dL).

         14. International normalized ratio (INR) &gt;1.3

         15. Total bilirubin (TB) &gt;2.0 times ULN at screening (Except for documented Gilbert's
             syndrome with bilirubin levels 20 micromole per liter (mcmol/L) to 90 mcmol/L (1.2 to
             5.3 mg/dL) and with a ratio of unconjugated/conjugated bilirubin that is
             commensurately higher).

         16. Platelet count &lt;130 Ã— 10^9/liter (L)

         17. Medical history of impaired hemostasis or use of anticoagulant medication (use of
             antiplatelet medications, such as low-dose, that is 81 mg, aspirin [ASA] or
             clopidogrel [Plavix] will be allowed).

         18. Uncontrolled thyroid disease.

         19. Type 1 diabetes mellitus.

         20. Known or suspected intolerance or hypersensitivity to the IP, closely-related
             compounds, or any of the stated ingredients.

         21. Known history of alcohol or other substance abuse within the last year or at any time
             during the study based on investigator's discretion. Weekly alcohol intake greater
             than 21 grams/day for males and 14 grams/day for females on average or inability to
             reliably quantify alcohol consumption based on investigator's judgment.

         22. Within 6 months of MRI and liver biopsy:

               -  Have used any IP.

               -  Have been enrolled in a clinical study (including vaccine studies) that, in the
                  investigator's opinion, may impact this Shire-sponsored study.

         23. Inability to safely obtain a liver biopsy.

         24. Females who are pregnant, planning to become pregnant, or are breastfeeding, or males
             who are planning to father a child during study participation.

         25. The anticipated need for a surgical procedure during the study that could interfere
             with the treatment.

         26. Known positivity for human immunodeficiency virus (HIV) infection.

         27. Cancer within 5 years of screening, except for basal or squamous cell carcinoma of the
             skin or in situ cervical carcinoma that has been treated with no evidence of
             recurrence.

         28. History of noncompliance with medical regimens, unreliability, mental instability or
             incompetence that could compromise the validity of informed consent or lead to
             noncompliance with the study protocol.

         29. Any other conditions or abnormalities which, in the opinion of the investigator, may
             compromise the safety of the subject, or interfere with the subject participating.

         30. Subject is currently enrolled in this study at any study site (unless the subject is
             transferring to another qualified study site with prior sponsor approval).

         31. Subjects who are employees at the unit of the investigational site that is conducting
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Mirum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresno Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ceders-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington (GW) Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Center of Gastroenterology</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates of Wellstar Atlanta Medical</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center - Liver Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health Inc.</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concorde Medical Group PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Liver Disease</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC-Gastroenterology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center for Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinsearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of TN Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>038104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Health Systems Clinical</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVM Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Digestive Health Center (DHC)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAIR Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Heath Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3HJ 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPR: Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Digestive Diseases Centre and Biomedical Research Unit</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abertawe Bro Morgannwg University</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research Facility</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <results_first_submitted>June 28, 2019</results_first_submitted>
  <results_first_submitted_qc>November 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD activity score</keyword>
  <keyword>ASBTi</keyword>
  <keyword>MRI PDFF</keyword>
  <keyword>NAS</keyword>
  <keyword>NAFLD</keyword>
  <keyword>liver disease</keyword>
  <keyword>ASBT</keyword>
  <keyword>MRI proton density fat fraction</keyword>
  <keyword>nonalcoholic steatohepatitis</keyword>
  <keyword>apical sodium dependent bile acid transporter inhibitor</keyword>
  <keyword>fatty liver</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volixibat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02787304/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02787304/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SHP626 5 Milligram (mg)</title>
          <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="P2">
          <title>SHP626 10 Milligram (mg)</title>
          <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="P3">
          <title>SHP626 20 Milligram (mg)</title>
          <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="P4">
          <title>Placebo (PBO)</title>
          <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50">One subject was randomized and received 1 dose of study drug but withdrew from the study.</participants>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SHP626 5 Milligram (mg)</title>
          <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="B2">
          <title>SHP626 10 Milligram (mg)</title>
          <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="B3">
          <title>SHP626 20 Milligram (mg)</title>
          <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="B4">
          <title>Placebo (PBO)</title>
          <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="196"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age was calculated as the difference between date of birth and date of informed consent, rounded down to the last whole year.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="14.13"/>
                    <measurement group_id="B2" value="53.0" spread="11.84"/>
                    <measurement group_id="B3" value="53.2" spread="13.61"/>
                    <measurement group_id="B4" value="53.4" spread="11.75"/>
                    <measurement group_id="B5" value="53.1" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48</title>
        <description>Binary response indicating (yes/no) whether a subject responded at week 48 with a reduction of at least 2 points, without worsening of fibrosis, from baseline nonalcoholic fatty liver disease (NAFLD) activity score (NAS). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Full Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48</title>
          <description>Binary response indicating (yes/no) whether a subject responded at week 48 with a reduction of at least 2 points, without worsening of fibrosis, from baseline nonalcoholic fatty liver disease (NAFLD) activity score (NAS). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
          <population>Full Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Liver Histology</title>
        <description>Change in liver histology will be measured by the individual NAS components (ballooning, inflammation, steatosis). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis (assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Liver Histology</title>
          <description>Change in liver histology will be measured by the individual NAS components (ballooning, inflammation, steatosis). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis (assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
          <population>Safety Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NAS - steatosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.82"/>
                    <measurement group_id="O2" value="-0.2" spread="0.87"/>
                    <measurement group_id="O3" value="-0.5" spread="0.93"/>
                    <measurement group_id="O4" value="-0.3" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAS - ballooning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.2" spread="0.75"/>
                    <measurement group_id="O3" value="0.0" spread="0.93"/>
                    <measurement group_id="O4" value="-0.7" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAS - inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.75"/>
                    <measurement group_id="O2" value="-0.5" spread="0.93"/>
                    <measurement group_id="O3" value="-0.5" spread="0.76"/>
                    <measurement group_id="O4" value="-0.7" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Hepatic Steatosis</title>
        <description>Change in hepatic steatosis will be evaluated by measuring the reduction of liver fat with magnetic resonance imaging-proton density fat-fraction (MRI-PDFF) and stratified by treatment group.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Hepatic Steatosis</title>
          <description>Change in hepatic steatosis will be evaluated by measuring the reduction of liver fat with magnetic resonance imaging-proton density fat-fraction (MRI-PDFF) and stratified by treatment group.</description>
          <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
          <units>absolute percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" spread="4.801"/>
                    <measurement group_id="O2" value="-1.31" spread="7.555"/>
                    <measurement group_id="O3" value="-3.89" spread="4.474"/>
                    <measurement group_id="O4" value="-1.34" spread="5.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Liver Histology</title>
        <description>Change in liver histology will be measured by fibrosis stage. Fibrosis stage is assessed on a scale of 0-4 with higher scores indicating more severe disease and lower scores indicating less severe disease (F0 = no fibrosis, F4 = cirrhosis).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Full Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Liver Histology</title>
          <description>Change in liver histology will be measured by fibrosis stage. Fibrosis stage is assessed on a scale of 0-4 with higher scores indicating more severe disease and lower scores indicating less severe disease (F0 = no fibrosis, F4 = cirrhosis).</description>
          <population>Full Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fibrosis Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.08"/>
                    <measurement group_id="O2" value="2.2" spread="0.98"/>
                    <measurement group_id="O3" value="1.5" spread="1.07"/>
                    <measurement group_id="O4" value="1.4" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis Score Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.13"/>
                    <measurement group_id="O2" value="2.2" spread="1.25"/>
                    <measurement group_id="O3" value="2.1" spread="1.25"/>
                    <measurement group_id="O4" value="1.3" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Resolution of NASH at Week 48</title>
        <description>Resolution of NASH is defined as total absence of ballooning [score = 0], absent or mild inflammation [score 0-1], steatosis can be present [score 0-3]) without worsening of fibrosis as assessed by liver histology at Week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>Safety Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Resolution of NASH at Week 48</title>
          <description>Resolution of NASH is defined as total absence of ballooning [score = 0], absent or mild inflammation [score 0-1], steatosis can be present [score 0-3]) without worsening of fibrosis as assessed by liver histology at Week 48.</description>
          <population>Safety Analysis Set for subjects with liver biopsy at both Baseline and Week 48 (post hoc analysis) at the time of the interim analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Serum Liver-related Biochemistry</title>
        <description>Serum liver-related biochemistry will be analysed by measuring alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Serum Liver-related Biochemistry</title>
          <description>Serum liver-related biochemistry will be analysed by measuring alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT).</description>
          <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="25.83"/>
                    <measurement group_id="O2" value="4.2" spread="33.65"/>
                    <measurement group_id="O3" value="-6.9" spread="37.91"/>
                    <measurement group_id="O4" value="-0.2" spread="24.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="16.57"/>
                    <measurement group_id="O2" value="10.6" spread="31.23"/>
                    <measurement group_id="O3" value="-7.2" spread="27.08"/>
                    <measurement group_id="O4" value="-0.8" spread="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="9.62"/>
                    <measurement group_id="O2" value="-0.9" spread="27.37"/>
                    <measurement group_id="O3" value="-0.1" spread="14.82"/>
                    <measurement group_id="O4" value="-0.7" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="46.24"/>
                    <measurement group_id="O2" value="5.2" spread="47.24"/>
                    <measurement group_id="O3" value="-8.8" spread="45.43"/>
                    <measurement group_id="O4" value="-8.5" spread="41.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Serum Liver-related Biochemistry</title>
        <description>Serum liver-related biochemistry will be analysed by measuring total bilirubin (TB).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Serum Liver-related Biochemistry</title>
          <description>Serum liver-related biochemistry will be analysed by measuring total bilirubin (TB).</description>
          <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.2198"/>
                    <measurement group_id="O2" value="0.124" spread="0.2872"/>
                    <measurement group_id="O3" value="0.060" spread="0.2730"/>
                    <measurement group_id="O4" value="0.058" spread="0.1762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Metabolic Indicators</title>
        <description>Metabolic indicators will be assessed by measuring fasting serum glucose levels and insulin levels.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis. For insulin levels, samples were collected but due to study termination for futility after the interim analysis, an analysis of this outcome measure was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Metabolic Indicators</title>
          <description>Metabolic indicators will be assessed by measuring fasting serum glucose levels and insulin levels.</description>
          <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis. For insulin levels, samples were collected but due to study termination for futility after the interim analysis, an analysis of this outcome measure was not performed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="40.07"/>
                    <measurement group_id="O2" value="-5.0" spread="23.11"/>
                    <measurement group_id="O3" value="1.6" spread="21.31"/>
                    <measurement group_id="O4" value="15.6" spread="45.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Metabolic Indicators</title>
        <description>Metabolic indicators will be assessed by measuring hemoglobin A1c (HbA1c).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Metabolic Indicators</title>
          <description>Metabolic indicators will be assessed by measuring hemoglobin A1c (HbA1c).</description>
          <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis.</population>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0003" spread="0.00559"/>
                    <measurement group_id="O2" value="-0.0008" spread="0.00552"/>
                    <measurement group_id="O3" value="-0.0020" spread="0.00426"/>
                    <measurement group_id="O4" value="0.0033" spread="0.00701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 on Serum Lipids</title>
        <description>Serum lipids level will be measured by calculating fasting total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglycerides.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SHP626 5 Milligram (mg)</title>
            <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O2">
            <title>SHP626 10 Milligram (mg)</title>
            <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O3">
            <title>SHP626 20 Milligram (mg)</title>
            <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO)</title>
            <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 on Serum Lipids</title>
          <description>Serum lipids level will be measured by calculating fasting total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglycerides.</description>
          <population>Safety Analysis Set (post hoc analysis) - for subjects with Week 48 data at the time of interim analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting total cholesterol change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="32.06"/>
                    <measurement group_id="O2" value="-19.1" spread="38.26"/>
                    <measurement group_id="O3" value="-7.6" spread="26.94"/>
                    <measurement group_id="O4" value="4.7" spread="30.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="6.72"/>
                    <measurement group_id="O2" value="2.2" spread="10.36"/>
                    <measurement group_id="O3" value="2.7" spread="6.56"/>
                    <measurement group_id="O4" value="0.0" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="27.38"/>
                    <measurement group_id="O2" value="-19.5" spread="31.78"/>
                    <measurement group_id="O3" value="-9.0" spread="22.37"/>
                    <measurement group_id="O4" value="-0.8" spread="26.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="37.05"/>
                    <measurement group_id="O2" value="-0.2" spread="92.34"/>
                    <measurement group_id="O3" value="-7.2" spread="71.62"/>
                    <measurement group_id="O4" value="28.7" spread="52.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Visit 10 (Week 52)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SHP626 5 Milligram (mg)</title>
          <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="E2">
          <title>SHP626 10 Milligram (mg)</title>
          <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="E3">
          <title>SHP626 20 Milligram (mg)</title>
          <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
SHP626: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
        </group>
        <group group_id="E4">
          <title>Placebo (PBO)</title>
          <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
Placebo: Matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="43" subjects_affected="38" subjects_at_risk="49"/>
                <counts group_id="E2" events="46" subjects_affected="35" subjects_at_risk="49"/>
                <counts group_id="E3" events="47" subjects_affected="35" subjects_at_risk="49"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>At the Week 24 Interim Analysis, no differences were observed between any dose of Volixibat and placebo based on absolute change in steatosis from baseline, as assessed by MRI hepatic PDFF, and % change from baseline in ALT; the study was terminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Mirum</organization>
      <phone>1 650-667-4085</phone>
      <email>medinfo@mirumpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

